<DOC>
	<DOCNO>NCT00890084</DOCNO>
	<brief_summary>To assess efficacy telmisartan hypertensive patient high cardiovascular risk</brief_summary>
	<brief_title>Telmisartan Tab Hypertension</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Telmisartan , hydrochlorothiazide drug combination</mesh_term>
	<criteria>Inclusion criterion : Hypertensive patient BP . 140/90mmHgand high high cardiovascular risk accord ESH/ESC Guidelines 2007 prescriber take decision start treatment telmisartan 40 80 mg , without HCTZ 12.5 mg 25 mg , usual way line SmPC reimbursement criterion Exclusion criterion : Contraindications Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>